全文获取类型
收费全文 | 5369篇 |
免费 | 396篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 242篇 |
妇产科学 | 129篇 |
基础医学 | 624篇 |
口腔科学 | 59篇 |
临床医学 | 1045篇 |
内科学 | 913篇 |
皮肤病学 | 78篇 |
神经病学 | 354篇 |
特种医学 | 164篇 |
外科学 | 525篇 |
综合类 | 176篇 |
一般理论 | 4篇 |
预防医学 | 705篇 |
眼科学 | 47篇 |
药学 | 363篇 |
中国医学 | 1篇 |
肿瘤学 | 320篇 |
出版年
2023年 | 24篇 |
2022年 | 38篇 |
2021年 | 99篇 |
2020年 | 68篇 |
2019年 | 114篇 |
2018年 | 114篇 |
2017年 | 101篇 |
2016年 | 106篇 |
2015年 | 117篇 |
2014年 | 157篇 |
2013年 | 293篇 |
2012年 | 416篇 |
2011年 | 382篇 |
2010年 | 237篇 |
2009年 | 190篇 |
2008年 | 386篇 |
2007年 | 384篇 |
2006年 | 381篇 |
2005年 | 394篇 |
2004年 | 381篇 |
2003年 | 349篇 |
2002年 | 354篇 |
2001年 | 40篇 |
2000年 | 36篇 |
1999年 | 44篇 |
1998年 | 66篇 |
1997年 | 44篇 |
1996年 | 42篇 |
1995年 | 41篇 |
1994年 | 26篇 |
1993年 | 24篇 |
1992年 | 25篇 |
1991年 | 21篇 |
1990年 | 23篇 |
1989年 | 23篇 |
1988年 | 16篇 |
1987年 | 17篇 |
1986年 | 12篇 |
1985年 | 12篇 |
1984年 | 20篇 |
1983年 | 27篇 |
1982年 | 16篇 |
1981年 | 19篇 |
1980年 | 10篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1974年 | 7篇 |
1973年 | 9篇 |
1972年 | 12篇 |
1971年 | 8篇 |
排序方式: 共有5789条查询结果,搜索用时 15 毫秒
111.
Jan Odom-Forren Leena Jalota Debra K. Moser Terry A. Lennie Lynne A. Hall Joseph Holtman Vallire Hooper Christian C. Apfel 《Journal of clinical anesthesia》2013,25(7):551-559
Study Objective1) To quantify the incidence and severity of postdischarge nausea and vomiting (PDNV) for 7 days in adults undergoing outpatient surgeries with general anesthesia; 2) to evaluate whether a risk model previously developed for the first two postoperative days may be used to predict the patient’s risk of PDNV for 7 days; and 3) to verify whether the same risk factors are applicable in the 3 to 7 day period.DesignProspective study.SettingTwo university-affiliated centers.Patients248 adult (> 18 years) surgical outpatients undergoing ambulatory surgical procedures with general anesthesia between 2007 and 2008.MeasurementsThe incidence and severity of PDNV and a simplified risk score for PDNV was assessed prospectively from discharge up to 7 postoperative days.Main ResultsThe overall incidence of nausea was 56.9% and of emesis was 19.4%. The incidence of PDNV was highest on the day of surgery (DOS), with PDNV of 44.8% and decreasing over time to 6.0% on day 7. Using the simplified risk score for PDNV the area under the receiver operating characteristic (ROC) curve was 0.766 (0.707, 0.825). A previous history of postoperative nausea and vomiting (PONV; OR 3.51, CI 1.70 - 7.27), operating room time (odds ratio [OR] 2.19, 95% CI 1.34 - 3.60), use of ondansetron in the Postanesthesia Care Unit (PACU; OR 6.39, CI 1.65-24.79), and pain during days 3–7 (OR 1.67, CI 1.30 - 2.14) were the strongest predictors of PDNV on days 3–7.ConclusionsPDNV affects a significant number of patients after ambulatory surgery, and our simplified PDNV score may be applied to a 7-day population. Pain appears to be a factor in late PDNV. It is possible that the presence of PDNV during days 3–7 has different origins from the PDNV that resolved over the first 48 hours. 相似文献
112.
113.
Sevgi Gurkan Billie Fyfe Lynne Weiss Xue Xiao Yuzhou Zhang Richard J. Smith 《Pediatric nephrology (Berlin, Germany)》2013,28(10):1975-1981
Background
Hyperactivity of the alternative complement pathway is the principle defect in C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds C5 to prevent formation of the membrane attack complex, has been shown to be beneficial in some patients with this disease.Methods
In this open-label, proof-of-concept efficacy-and-safety study, a patient with the initial diagnosis of dense deposit disease (DDD) and allograft recurrence of C3 glomerulonephritis (C3GN) was treated with eculizumab every other week for 1 year. The patient had pathological evidence of C3GN and proteinuria >1 g/day at enrollment. He underwent graft biopsy before enrollment and repeat biopsy at 6 and 12 months.Results
Although no mutations were identified in complement genes, functional studies were positive for C3 nephritic factors and elevated levels of soluble membrane attack complex (sMAC). On therapy, sMAC levels normalized and although proteinuria initially decreased, it increased reaching pre-treatment levels at 12 months. Although serum creatinine remained stable, repeat allograft biopsies showed progression of disease.Conclusions
Clinical and histopathologic data suggest a partial response to eculizumab in this patient. While eculizumab blocked activation of the terminal complement cascade, persistent dysregulation of the alternative pathway remained, indicating eculizumab alone cannot control disease in this patient. Additional research is required to identify effective anticomplement therapy for this group of C3G patients. 相似文献114.
115.
Nancy L. Brackett PhD HCLD Emad Ibrahim MD Andrei Krassioukov MD PhD Charles M. Lynne MD 《The journal of spinal cord medicine》2013,36(3):272-275
AbstractBackground/Objective: Three patients with spinal cord injury (SCI) and 3 able-bodied (AB) patients were infused with naloxone during a study to examine their neuroendocrine function. An unanticipated side effect occurred during the naloxone infusion. All 3 patients with SCI, but none of the AB patients, experienced profoundly increased spasticity during the naloxone infusion. Our report describes this side effect, which has potential implications for the clinical treatment or scientific evaluation of individuals with SCI.Methods: All patients were in good general health and medication free for 11 days or longer before the study. Each patient was placed on a 30-hour protocol to analyze pulsatile release of gonadotropins. Physiologic saline was intravenously infused on day 1 to serve as a control period for naloxone infusion on day 2.Results: AB patients experienced no muscle spasm activity or any other side effects at any time during the study. In contrast, all 3 patients with SCI experienced a profoundly increased frequency and duration of spasticity in muscles innervated by the nerve roots caudal to their level of injury. In all 3 patients with SCI, spasticity increased only during the period of naloxone infusion. Within 1 hour of stopping naloxone, spasticity returned to baseline levels.Conclusions: Naloxone infusion produced a differential effect on the muscle activity of men with SCI compared to AB men with intact spinal circuits. Consistent with previous studies, the results of this study indicate a relationship between opioid neuromodulation and spasticity after SCI. 相似文献
116.
117.
Are there cognitive and neurobehavioural correlates of hormonal neuroprotection for women after TBI?
Janet P. Niemeier Jennifer H. Marwitz William C. Walker Lynne C. Davis Tamara Bushnik David L. Ripley 《Neuropsychological rehabilitation》2013,23(3):363-382
This study examined possible cognitive correlates of hormonal neuroprotection following traumatic brain injury (TBI) using archival neuropsychological findings for 1563 individuals undergoing acute TBI rehabilitation between 1989 and 2002. Presumed age of menopause was based on the STRAW (Stages of Reproductive Aging) staging system (Soules, 2005; Soules et al., 2001) and general linear model (GLM) analysis of performance on neuropsychological testing by participants across gender and age groups (25–34, 35–44, 45–54, and 55–64) was performed. Hypotheses were (1) women with TBI in the oldest age group would have lower scores on neuropsychological tests and functional outcome measures than women in the younger groups, and (2) men in the oldest age group would have higher scores than women of the same age group. Analyses revealed that oldest females had significantly worse Trails B and SDMT written and oral scores than the youngest females. In addition, oldest females had significantly better Trails B, Rey AVLT and SDMT written scores than the oldest males. Possible cohort exposure to hormone replacement therapy, unknown hormonal status at time of testing, and sample-specific injury characteristics may have contributed to these findings. 相似文献
118.
Randomized controlled trial of a book‐sharing intervention in a deprived South African community: effects on carer–infant interactions,and their relation to infant cognitive and socioemotional outcome 下载免费PDF全文
119.
120.
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants 下载免费PDF全文
Zorrilla CD Van Dyke R Bardeguez A Acosta EP Smith B Hughes MD Huang S Watts DH Heckman B Jiménez E McSherry G Mofenson L 《Antimicrobial agents and chemotherapy》2007,51(6):2208-2210
Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia). 相似文献